Immunogenicity and Safety of Vaccine Against Tetanus and Diphtheria.

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

December 12, 2022

Primary Completion Date

March 4, 2024

Study Completion Date

June 30, 2024

Conditions
DiphtheriaTetanus
Interventions
BIOLOGICAL

Clodivac

A dose of 0.5 ml should be administered intramuscularly into deltoid muscle.

BIOLOGICAL

Td-Impfstoff Merieux

One dose (0.5 ml) intramuscular, preferably in the deltoid muscle of the upper arm.

Trial Locations (2)

Unknown

SPZOZ w Bochni Szpital Powiatowy im. bł. M. Wieckiej, Bochnia

Krakowski Szpital Specjalistyczny im. Jana Pawła II, Krakow

Sponsors

Lead Sponsor

All Listed Sponsors
lead

IBSS Biomed S.A.

INDUSTRY